Adenylyl cyclase-associated protein 1-targeted nanoparticles as a novel strategy for the treatment of metastatic non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is one of the most fatal cancers worldwide. Adenylyl cyclase-associated protein 1 (CAP1) belongs to a family of cyclase-associated proteins that are involved in the development of cancerous tumors. A previous study by our group confirmed the association between CAP1, lung cancer and the metastasis of cancer cells. In the present study, poly(lactic-polyglycolic acid; PLGA)/CAP1-small interfering (si)RNA nanoparticles were prepared and delivered into A549 cells. The performance of PLGA/siCAP1-siRNA nanoparticles for siRNA delivery was measured based on the results of migration assay and animal experiments. The multifunctional nanoparticles were determined to be capable of inhibiting CAP1 expression, which reduced NSCLC metastasis in vitro and in vivo. Therefore, the findings of the current study highlighted the potential use of PLGA/siCAP1-siRNA nanoparticles for the treatment of NSCLC metastasis.